CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: January 7, 2013
Result type: Reports
Project Number: SR0304-000
Product Line: Reimbursement Review

Generic Name: Eculizumab

Brand Name: Soliris

Manufacturer: Alexion Pharma Canada

Therapeutic Area: Hemolytic Uremic Syndrome, Atypical

Indications: Hemolytic Uremic Syndrome, Atypical

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 18, 2013

Recommendation Type: Do not list